
## **Christof Bernemann**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/198595/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients. Scientific Reports, 2022, 12, .	1.6	4
2	Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving <sup>177</sup> Lu-PSMA-617 Radioligand Therapy. Theranostics, 2020, 10, 7645-7655.	4.6	23
3	Correlation between SFRP1 expression and clinicopathological parameters in patients with triple-negative breast cancer. Future Oncology, 2019, 15, 1921-1938.	1.1	13
4	Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer. Clinical Cancer Research, 2019, 25, 3856-3864.	3.2	17
5	Considerations for AR-V7 testing in clinical routine practice. Annals of Translational Medicine, 2019, 7, S378-S378.	0.7	4
6	Performance comparison of two androgen receptor splice variant 7 (ARâ€V7) detection methods. BJU International, 2018, 122, 219-226.	1.3	11
7	Reverse engineering of triple-negative breast cancer cells for targeted treatment. Maturitas, 2018, 108, 24-30.	1.0	3
8	Novel AR-V7 detection in whole blood samples in patients with prostate cancer: not as simple as it seems. World Journal of Urology, 2017, 35, 1625-1627.	1.2	7
9	Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. I Clin Oncol 2017:35:2149–56. European Urology. 2017. 72. e168-e169.	0.9	9
10	Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. European Urology, 2017, 71, 1-3.	0.9	113
11	Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7–Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4–6. European Urology, 2017, 71, 6-7.	0.9	5
12	Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1–3. European Urology, 2017, 71,	0.9	1
13	e107-e108. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling. Molecular Cancer, 2014, 13, 174.	7.9	45